Safety and Efficacy of Venlafaxine XR in Elderly Patients With Major Depression
This research study is to evaluate the safety and usefulness of venlafaxine-XR in the treatment of major depression in the elderly.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Safety and Efficacy of Venlafaxine XR in Elderly Patients With Major Depression|
- The safety and tolerability of venlafaxine XR.
- Rate of Major Depression remission to treatment.
- Participant characteristics that influence safety and remission rate.
|Study Start Date:||October 2000|
|Primary Completion Date:||November 2004 (Final data collection date for primary outcome measure)|
The primary objective of this pilot study is to evaluate the safety of venlafaxine extended release formulation (XR) in the treatment of geriatric non-psychotic depression. This pilot study's specific aims are to assess the safety of venlafaxine XR in the geriatric population, to estimate the response rate of older depressed subjects treated under open conditions and to evaluate pharmacokinetic characteristics that may impact on safety and outcome.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00177528
|United States, Pennsylvania|
|University of Pittsburgh Medical Center|
|Pittsburgh, Pennsylvania, United States, 15213|
|Principal Investigator:||Ellen M Whyte, MD||University of Pittsburgh|
|Principal Investigator:||Benoit H Mulsant, MD||University of Pittsburgh|
|Principal Investigator:||Charles F. Reynolds III, MD||University of Pittsburgh|